Korean pharmaceutical industry has potentiality in biotec.

Mr. Robert A. Ingram, the CEO of Glaxo Smith Kline, who visited to Korea on March 11 took a press interview on 13, advising that the R&D of bio technology in the pharmaceutical industry should be closely bound with the business capacity. He added to say that the R&D for the new drug discovery took an enormous investment for over 10 to 15 years through many complicated and overlapped clinical st...